CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for early breast cancer: drug combo aims to stop recurrence
Disease control Recruiting nowThis study is testing whether adding the drug dalpiciclib to standard hormone therapy can help keep early-stage HR+/HER2- breast cancer from returning. About 2000 women with stage II or III breast cancer will receive either a lower dose for 3 years or a higher dose for 2 years. R…
Matched conditions: CDK4/6 INHIBITOR
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New study tracks breast cancer return in patients on targeted therapy
Knowledge-focused Recruiting nowThis study observes 750 people with a common type of breast cancer who have already been treated with surgery and are now taking CDK4/6 inhibitors to lower the risk of cancer coming back. Researchers will track how many patients experience a relapse and how well they do over time…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:11 UTC